Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

INTRANASAL DRUG DELIVERY - A US MARKET REPORT   

Research Abstract

This report analyzes the US market for Intranasal Drug Delivery in US$ Million by the following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a six-year historic analysis is provided for this market. The report profiles 77 companies including many key and niche players such as Aegis Therapeutics LLC, Alza Corporation, AptarGroup, Inc., Archimedes Pharma Limited., AstraZeneca Plc., MedImmune, Inc., Bayer Consumer Care, Bespak Plc., GlaxoSmithKline Plc, Ikano Therapeutics Inc., Javelin Pharmaceuticals, Inc., Kurve Technology, Inc., Marina Biotech, Inc., Merck & Co., Inc., Novartis AG, OptiNose AS, Pfizer, Inc., Rexam Plc, Sanofi-Aventis S.A., and Unigene Laboratories, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1795
Price : $4500
Companies : 77
Pages : 393
Date : January 2011
Market Data Tables : 10

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  INTRANASAL DRUG DELIVERY (Complete Report) Pages : 393   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......13 $295  
   Study Reliability and Reporting Limitations.......1  
   Disclaimers.......2
Data Interpretation & Reporting Level.......2
  
   Quantitative Techniques & Analytics.......3
Product Definitions and Scope of Study.......3
  
  2. INDUSTRY OVERVIEW.......49 $900  
   Drug Delivery: A Quick Primer.......4
The Nose: An Attractive Avenue to Cross the Blood Brain Barrier.......4
1$100
   Self-Administration of Drugs Brings Intranasal Drug Delivery Into the
  Spotlight.......5
Research & Technology Opens Up New Therapeutic Areas for Nasal Drug Delivery.......5
1$100
   Product Developments in the US Intranasal Drug Delivery Market: 2007.......6
R&D: Critical to the Commercialization of Intranasal Drug Delivery.......6
Tight Junction Biology: A Key Speed Breaker in Commercialization.......6
1$100
   RNA Interference (RNAi): A Tool to Manipulate Tight Junctions.......7
Why Is Nasal Drug Delivery the Theme of All Drug Delivery Research Projects?.......7
Nasal Drug Delivery Devices & Equipment.......7
Preservative Free Systems (P.F.S.).......7
2$200
   Traditional Vs. Advanced Intranasal Drug Delivery Devices.......9
Pitfalls Of Traditional Delivery Devices.......9
The Promise of New Advanced Delivery Devices.......9
Bi-Directional Nasal Drug Delivery: A Technology With a Huge Potential.......9
1$100
   Benefits of Bi-Directional Delivery Authenticated Through Research Studies.......101$100
   Market for Nasal Spray Devices in the US.......11
GSK Looses Share to Merck, Following Patent Expiry of Flonase.......11
Table 1: US Intra-Nasal Steroid Market for Allergic Rhinitis: Sales of Leading Nasal Formulations for 2008 (includes corresponding Graph/Chart).......11
1$350
   Table 2: The US Nasal Drug Delivery Market for Allergic Rhinitis: Sales Of Top Four Nasal Steroid Formulations for The Year 2005 (In US$ Million) (includes corresponding Graph/Chart).......121$100
  3. MARKET DYNAMICS.......134 $400  
   Innovation in Drug Delivery: A Talisman For Success.......13
Controlled Release Technology Is the Buzz Word.......13
Target-Specific Delivery Devices: Of Critical Value.......13
Safety and Cost: Primary Growth Drivers.......13
1$100
   Preservatives Losing Sheen in Nasal Spray Formulations.......14
Multi-Dose Containers Evolve to Offer Resistance Against Microbial
  Contamination.......14
Bioavailability: An Important Facet of Intranasal Drug Delivery.......14
1$100
   Chemical Modification.......15
Transient Modification & Limited Enzymatic Activity.......15
Bioavailability of Large Molecules.......15
Bio-Adhesive Polymers: Useful in Increasing Drug Absorption.......15
Mixed Opinions on Efficiency of Calcitonin Nasal Spray.......15
1$100
   Nasal Preparations Gaining Foothold in Cough and Allergic Categories.......16
Patent Expiries Impact Market Opportunities.......16
1$100
  4. TECHNOLOGY OVERVIEW.......1710 $1000  
   Intranasal Drug Delivery: A Descriptive Exposition.......17
Nasal Physiology.......17
1$100
   Challenges Involved In Formulating Nasal Drugs.......181$100
   The Importance of Bioadhesion.......19
Challenges Involved In Designing Devices.......19
1$100
   Overview of the Traditional Drug Administration Routes, Molecular Weight
  Capabilities, and Dosage Range.......20
Intranasal Drugs - Prescription (Rx) and Over-the- Counter (OTC).......20
Differences Between Systemic Delivery and Local Effects.......20
1$100
   Nasal Powders Vs Sprays.......21
Nasal Drug Delivery Devices.......21
1$100
   Types of Drug Delivery Devices.......22
Droppers.......22
Sprays.......22
Aerosol Containers/Inhalers.......22
Pumps.......22
Nasal Aspirator.......22
Intranasal Drug Delivery Vis-à-vis Other Delivery Techniques.......22
1$350
   Table 3: US Market for Intranasal Drugs: Percentage share of Topical and Systemic Drugs by value for the Years 2006 and 2015.......23
Limitations of Intranasal Drug Delivery.......23
Allergy.......23
Definition.......23
1$100
   Symptoms.......24
Allergic Rhinitis.......24
Nasal Allergies.......24
1$350
   Table 4: US Market for Nasal Sprays: Top Five Nasal Sprays for Cough, Cold, Sinus and Allergy Ranked by Dollar Retail Sales for the Year Ended January 2008 (In US $ Million) (includes corresponding Graph/Chart).......25

Table 5: US Market for Nasal Sprays, Drops and Inhalers: Top 10 Brands Ranked by Dollar Sales Through Drug Stores for the Year Ended January 2008 (In US $ Million) (includes corresponding Graph/Chart).......25
1$350
   Table 6: US Market for Nasal Sprays, Drops and Inhalers: Top 10 Brands Ranked by Unit Sales Through Drug Stores for the Year Ended January 2008 (In Thousand Units) (includes corresponding Graph/Chart).......261$100
  5. NASAL DRUGS: AN OVERVIEW.......2711 $1100  
   Nasal Drugs for Allergies.......27
Corticosteroid Nasal Sprays.......27
Flonase.......27
Patanase.......27
1$100
   Beconase.......28
Other Nasal Corticosteroid Drugs.......28
Antihistamine Nasal Sprays.......28
Astelin Nasal Spray.......28
Otrivin Nasal Spray.......28
Livostin Nasal Spray.......28
1$100
   Other Nasal Antihistamine Drugs.......29
Select Brands of Allergy Relievers.......29
Nasal Drugs for Postmenopausal Osteoporosis.......29
Calcitonin–Salmon Nasal Spray.......29
Miacalcin Nasal Spray.......29
Fortical® Nasal Spray.......29
1$100
   Intranasal Pain Management Drugs.......30
Stadol Nasal Spray.......30
1$100
   Rylomine.......31
Imitrex.......31
Migranal.......31
Zolmitriptan Nasal Spray.......31
Intranasal Analgesics For Treating Migraine.......31
1$100
   Select Intranasal Pain Management Products in Development.......32
Intranasal Vaccination.......32
1$100
   Process of Intranasal Immunization.......33
Market Drivers.......33
1$100
   “LAIV” Nasal Spray Flu Vaccine.......34
FluMist® Vaccine From MedImmune.......34
Intranasal Drugs for Sexual Dysfunction.......34
1$350
   Table 7: US Market for Intranasal Sexual Dysfunction Drugs: Revenues for the Years 2010 through 2012 in US$ Million (includes corresponding Graph/Chart).......35
Nasal Spray for Treating Vitamin B12 Deficiency.......35
Nasal Spray for Aiding Smoking Cessation.......35
1$100
   Intranasal Drugs in Pipeline: 2008 and 2009.......361$100
   Other Intranasal Drugs in Pipeline.......371$100
  6. SELECT RESEARCH & DEVELOPMENT INITIATIVES.......389 $900  
   Nastech Enrolls 551 Patients for Phase 2 Trials of PYY3-36 Nasal Spray.......38
Archimedes Pharma Commences Phase III Trials for NasalFent®.......38
Archimedes Presents New Clinical Data on NasalFent®.......38
LigoCyte Commences Clinical Trials for Intranasal Norovirus Vaccine.......38
1$100
   Javelin Pharmaceuticals Reveals Phase 2 Study Results for PMI-100/150.......39
Javelin Pharmaceuticals Commences Phase III studies for PMI-150.......39
Nastech Commences Phase 2 Trials for Insulin Nasal Spray.......39
ACAAI Reveals Results for Trials of Nasacort® AQ Nasal Spray in Children.......39
1$100
   TGAR01H from Fabre Kramer.......40
Aegis Therapeutics Completes First Human Clinical Study on Intravail®.......40
Nastech Pharmaceutical Presents Clinical Test Results on Parathyroid Hormone.......40
1$100
   Zolmitriptan Promises Relief for Cluster Headaches.......41
CAIV-T: More Effective than Injectable Influenza Vaccines.......41
Intranasal Therapeutics Conducts Study on Midazolam.......41
1$100
   Nastech Announces Phase I Results of Insulin Nasal Spray.......42
Archimedes Completes Phase II Trials of NASALFENT.......42
Intranasal Corticosteroid Proven Effective for Treating Allergic Rhinitis.......42
1$100
   Aegis Files DMF for Intravail.......43
Nasal Sprays: A New-Generation Treatment for Gynecological Problems.......43
Aegis Therapeutics Conducts Feasibility Study on Drug Delivery Technology.......43
1$100
   GelVac Powder Delivery System Completes Phase I Clinical Trial.......44
OptiNose Develops Intranasal Delivery System for Osteoporosis.......44
1$100
   Nastech Initiates Dose Ranging Study of PYY(3-36).......45
Valois Develops New Nasal Dispensing System.......45
Rigel Pharmaceuticals to Initiate R112 Phase II Clinical Trial.......45
1$100
   MedPointe Pharmaceuticals Demonstrates ACT1 Study Results on ASTELIN®.......46
Bentley Pharmaceuticals Demonstrates Clinical Trial Results of its Intra Nasal Insulin
  Spray.......46
1$100
  7. RECENT TECHNOLOGICAL DEVELOPMENTS.......472 $200  
   New-Generation Technologies and Devices.......47
ViaNase from Kurve Technology.......47
A New Product from OptiNose.......47
1$100
   Nastech’s “Tight Junction Biology” Research Program.......48
ChiSys™ Nasal Delivery Technology from Archimedes.......48
1$100
  8. PRODUCT INNOVATIONS/INTRODUCTIONS.......492 $200  
   TheraBiogen to Introduce TheraMax Cold & Flu Nasal Spray.......49
Sinus Dynamics™ Unveils NasaTouch™ Nasal Delivery Device.......49
3M Drug Delivery Systems Introduces Nasal MDI.......49
MeadWestvaco Introduces Preservative-Free Nasal Pumps.......49
1$100
   GlaxoSmithKline Introduces Avamys Nasal Spray.......501$100
  9. PRODUCT INNOVATIONS/INTRODUCTIONS IN THE RECENT PAST- A PERSPECTIVE
  BUILDER.......51
3 $300  
   Aegis Therapeutics Develops ProTek™.......51
Heel Launches Luffeel® in the US.......51
Archimedes to Introduce Intranasal Formulation of Human Growth Hormone.......51
Sinofresh Launches SinoFresh™ Nasal & Sinus Care.......51
1$100
   PARI Respiratory Launches Nasal Drug Delivery Program.......52
OptiNose to Develop New Range of Intranasal Products.......52
OptiNose and Cambridge Consultants to Develop Advanced Nasal Delivery Device.......52
Kurve Technology Develops ViaNase ID™.......52
1$100
   Upsher-Smith Introduces Fortical® Nasal Spray.......53
Schering-Plough Launches New Formulation of NASONEX®.......53
AstraZeneca Unveils Rhinocort Aqua in the US.......53
1$100
  10. RECENT INDUSTRY ACTIVITY.......546 $600  
   Upsher-Smith Acquires ITI-111 from Ikano Therapeutics.......54
Hospira Acquires Javelin Pharmaceuticals.......54
Archimedes Pharma Receives Approval for PecFent Nasal Spray.......54
1$100
   Cypress Bioscience Obtains Patent Rights for Carbetocin Therapy.......55
MDRNA, Inc. Announces Change of Name.......55
Prosonix Inks Product Co-Development and Licensing with Trimel Biopharma.......55
1$100
   Serenity Pharmaceuticals and Allergan Sign Agreement.......56
Ethicon Acquires Acclarent.......56
Ikano’s Midazolam Obtains Orphan Drug Designation.......56
FDA Issues Not-Approvable Letter for Nastech’s Generic Calcitonin-Salmon.......56
1$100
   Trimel BioPharma Acquires Direct Haler.......57
Lupin Takes Over AllerNaze™ Rights from Collegium Pharmaceutical.......57
Nanotherapeutics Purchases DelSite Assets.......57
1$100
   Schering-Plough Merges with Merck.......58
Valois Pharma and Nycomed Launch Spray Pump for Fentanyl.......58
Phylogica and Aegis Therapeutics Collaborate.......58
Intranasal Therapeutics is Now Ikano Therapeutics.......58
FDA Clears Use of New Clone in Calcitonin Production of Unigene.......58
1$100
   Zelos Therapeutics Collaborates with Aegis Therapeutics.......59
ImmuneRegen BioSciences Partners with LRRI.......59
Avamys™ Nasal Spray Receives Approval in Europe.......59
PMI-150 Receives Canadian Patent.......59
1$100
  11. CORPORATE ACTIVITY IN THE RECENT PAST-A PERSPECTIVE BUILDER.......6012 $1200  
   Javelin Releases Phase III Data of Rylomine Intranasal Morphine.......60
FDA Recommends Supplemental Study for Javelin’s PMI-150.......60
Palatin Re-Acquires Bremelanotide Rights from King Pharma.......60
1$100
   USFDA Approves FluMist® for Young Children.......61
USFDA Approves Veramyst Nasal Spray for Individuals Aged Two Years and Above.......61
Kurve Technology Inks Agreement with Schering-Plough.......61
MedImmune Clarifies FDA Observations.......61
FluMist(R) Receives FDA Approval for Refrigerated Formulation.......61
Nastech Regains Rights for PTH1-34 Nasal Spray.......61
1$100
   NASONEX(R) Receives Ease-of-Use Commendation from Arthritis Foundation.......62
Aegis Therapeutics Establishes Cedar Therapeutics Inc........62
EMEA Provides Encouraging Feedback for Avamys™ Nasal Spray.......62
Kurve Technologies Introduces Blog on Nasal Drug Delivery.......62
Accentia Extends Agreement with Mayo Foundation.......62
1$100
   Nastech Signs Development and License Agreement with Amylin.......63
MedImmune's FluMist Plant Gets FDA Approval.......63
ShinNippon Subsidiaries Sign Licensing Agreement with Tokai Pharmaceuticals.......63
MeadWestvaco Acquires Saint-Gobain Calmar.......63
1$100
   Merck Terminates PYY3-36 Partnership with Nastech.......64
Inspire Signs Licensing Agreement with Boehringer Ingelheim.......64
P&G Partners with Nastech to Develop PTH(1-34).......64
1$100
   Unigene Laboratories Signs Distribution Agreement with Tzamal Bio Pharma.......65
GlaxoSmithKline Seeks Marketing Approval for Fluticasone Furoate in the US and
  Europe.......65
Kurve Technology Relocates Corporate Headquarters.......65
Kurve Inks an Agreement with DARA BioSciences.......65
1$100
   Kurve Enters into a Development Agreement with Schering-Plough.......66
Altana Submits NDS for Approval of Ciclesonide Nasal Spray in Canada.......66
Altana Pharma AG Receives FDA Approval for Pediatric Use of Omnaris.......66
Intranasal Therapeutics Inc. Receives Financial Funding.......66
FDA Completes Pre-Approval Inspections at Nastech’s Washington Facility.......66
1$100
   Kos Signs Exclusive License Agreement with SkyePharma.......67
Bentley Signs Agreement with Biocon.......67
Intranasal Therapeutics Files Patent Application for Synthetic THC.......67
Ionix Pharmaceuticals in Collaboration with Reckitt Benckiser for Drug
  Development.......67
1$100
   University of Kentucky Receives Patent for new Intranasal Device.......68
Intranasal Technology Extends Collaboration with Aegis Therapeutics.......68
Accentia Biopharmaceuticals Signs License Agreement with Collegium
  Pharmaceuticals.......68
1$100
   Aegis Therapeutics Extends License Agreement with Intranasal Technologies.......69
Bentley Pharmaceuticals Signs Agreement with Dong Sung Pharmaceuticals.......69
Unigene Gets FDA Approval for Fortical Calcitonin- Salmon Nasal Spray.......69
OptiNose Signs Collaborative Agreement with MedPharm.......69
1$100
   West Pharmaceutical Divests Drug Delivery Business to Archimedes Pharma.......70
Nastech Pharmaceutical Receives FDA Approval for Nascobal Nasal Spray.......70
Par and Nastech Sign Licensing Agreement.......70
Aegis Therapeutics Signs Licensing Agreement with University of Alabama.......70
1$100
   ITI Receives a Patent for Sedation Inducing Nasal Drug.......71
Inyx Bags Order from Australian OTC Drug Company.......71
1$100
  12. FOCUS ON SELECT GLOBAL PLAYERS.......727 $700  
   Aegis Therapeutics LLC (USA).......72
Alza Corporation (USA).......72
AptarGroup, Inc. (USA).......72
1$100
   Archimedes Pharma Limited. (UK).......73
AstraZeneca Plc. (UK).......73
MedImmune, Inc. (USA).......73
1$100
   Bayer Consumer Care (USA).......74
Bespak Plc. (UK).......74
GlaxoSmithKline Plc (UK).......74
1$100
   Ikano Therapeutics Inc. (USA).......75
Javelin Pharmaceuticals, Inc. (USA).......75
1$100
   Kurve Technology, Inc. (USA).......76
Marina Biotech, Inc. (USA).......76
Merck & Co., Inc. (USA).......76
1$100
   Novartis AG (Switzerland).......77
OptiNose AS (Norway).......77
Pfizer, Inc. (USA).......77
1$100
   Rexam Plc (UK).......78
Sanofi-Aventis S.A. (France).......78
Unigene Laboratories, Inc. (USA).......78
1$100
  13. MARKET ANALYTICS.......793 $1050  
   Table 8: US Recent Past, Current & Future Analysis for Intranasal Drug Delivery by Therapeutic Area – Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......791$350
   Table 9: US Historic Review for Intranasal Drug Delivery by Therapeutic Area – Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......801$350
   Table 10: US 11-Year Perspective for Intranasal Drug Delivery by Therapeutic Area –Percentage Breakdown of Values Sales for Allergic Infections, Analgesics, Osteoporosis, and Vaccinations for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......811$350
COMPETITION 306$995
  
Total Companies Profiled: 77 (including Divisions/Subsidiaries - 93)

Region/Country                 Players


The United States                 56   
Canada                             2
Japan                              3
Europe                            27
     France                        3
     Germany                       5
     The United Kingdom           13
     Rest of Europe                6
Asia-Pacific (Excluding Japan)     5
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign